Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer

Trial Profile

Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Celltrion
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 09 Sep 2017 Results presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to a Celltrion Healthcare media release.
    • 09 Sep 2017 Results presented in a Celltrion Healthcare Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top